5.0 REferences

5. USFDA Guidelines-21 CFR Part 320 Bioequiv. and Bioavail. requirements, section 320.1Definitions.
12. Epilepsy Foundation of America Inc., entre for Disease Control and Prevention (Grant No. 5U58DP00606-03, 2009).
13. Material Safety Data Sheet (2006), TOPIRAMATE, October 6,


38. ICH guideline M3 (R2) on non-clinical safety datas for the conduct of human clinical trials and marketing authorisation for pharmaceuticals; Step 5 (2009).
42. Basics of LC/MS: A Primer. Agilent Technologies.
45. E. J. Williams (1948), Experimental designs balanced for the residual effects of treatment, Australian Journal of Scientific Research, 2, 149-168.
50. Luca Spaccapelo, Silvia Leschiutta, Claudio Aurea1 and Anna Ferrari (2009), Topiramate-associated acute glaucoma in a migraine patient receiving concomitant citalopram therapy: a case-Journal report.
58. Shang-Peng Wu, Jing-Jane Tsai, Po-Wu Gean (1998), Frequency-dependent inhibition of neuronal activity by topiramate in rat hippocampal slices, British Journal of Pharmacology, 125, 826-832.

